Patrik Ernfors Selected Research

vacquinol-1

1/2021	Glioblastoma cytotoxicity conferred through dual disruption of endolysosomal homeostasis by Vacquinol-1.
2/2018	Evaluating vacquinol-1 in rats carrying glioblastoma models RG2 and NS1.
1/2016	The Oncolytic Efficacy and in Vivo Pharmacokinetics of [2-(4-Chlorophenyl)quinolin-4-yl](piperidine-2-yl)methanol (Vacquinol-1) Are Governed by Distinct Stereochemical Features.
10/2014	RETRACTED: Vulnerability of glioblastoma cells to catastrophic vacuolization and death induced by a small molecule.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Patrik Ernfors Research Topics

Disease

5	Pain (Aches) 01/2023 - 07/2009
4	Glioblastoma (Glioblastoma Multiforme) 06/2022 - 01/2016
3	Hypersensitivity (Allergy) 01/2022 - 07/2009
2	Diabetic Neuropathies (Diabetic Neuropathy) 12/2023 - 01/2022
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 12/2023 - 01/2022
2	Hyperglycemia 01/2022 - 06/2002
2	Hyperalgesia 01/2021 - 01/2017
2	Parkinson Disease (Parkinson's Disease) 12/2018 - 02/2013
2	Huntington Disease (Huntington's Disease) 06/2005 - 09/2004
1	Polyneuropathies (Polyneuropathy) 12/2023
1	Arthritis (Polyarthritis) 01/2023
1	Rheumatoid Arthritis 01/2023
1	Glioma (Gliomas) 06/2022
1	Neoplasms (Cancer) 06/2022
1	Labor Pain 01/2020
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2020
1	Hypoxia (Hypoxemia) 12/2018
1	Brain Neoplasms (Brain Tumor) 02/2018
1	Inflammation (Inflammations) 01/2018
1	Neuralgia (Stump Neuralgia) 01/2017
1	Mandibulofacial Dysostosis (Treacher Collins Syndrome) 04/2015
1	Alopecia (Baldness) 04/2015
1	Muscle Spasticity (Spastic) 11/2014
1	Paresis (Hemiparesis) 11/2014
1	Cerebrotendinous Xanthomatosis 11/2014
1	Inborn Genetic Diseases (Disease, Hereditary) 11/2014
1	Disease Progression 10/2014
1	Rupture 10/2014
1	Seizures (Absence Seizure) 12/2005
1	Neurodegenerative Diseases (Neurodegenerative Disease) 06/2005
1	Body Weight (Weight, Body) 03/2004
1	Hypercholesterolemia 06/2002

Drug/Important Bio-Agent (IBA)

4	vacquinol-1IBA 01/2021 - 10/2014
2	Carisoprodol (Soma)FDA LinkGeneric 12/2023 - 01/2021
2	AntibodiesIBA 12/2023 - 01/2023
2	Adenosine Triphosphate (ATP)IBA 01/2021 - 10/2014
2	Ion Channels (Ion Channel)IBA 04/2011 - 07/2009
2	Brain-Derived Neurotrophic Factor (BDNF)IBA 06/2005 - 09/2004
1	N 30IBA 12/2023
1	Proteins (Proteins, Gene)FDA Link 01/2023
1	acetyl 4-aminosalicylic acidIBA 01/2023
1	Anti-Citrullinated Protein AntibodiesIBA 01/2023
1	RNA (Ribonucleic Acid)IBA 06/2022
1	Streptozocin (Streptozotocin)FDA Link 01/2022
1	NAD (NADH)IBA 01/2022
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 01/2020
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 12/2018
1	Transcription Factors (Transcription Factor)IBA 12/2018
1	Carrier Proteins (Binding Protein)IBA 01/2018
1	Pain-FreeIBA 01/2018
1	Gabapentin (Neurontin)FDA LinkGeneric 01/2017
1	MicroRNAs (MicroRNA)IBA 01/2017
1	Calcium Channels (Calcium Channel)IBA 01/2017
1	quinolineIBA 01/2016
1	Methanol (Carbinol)IBA 01/2016
1	Endothelin Receptors (Endothelin Receptor)IBA 04/2015
1	cholestenoic acidIBA 11/2014
1	EnzymesIBA 11/2014
1	LigandsIBA 02/2013
1	Neuropeptide Y Receptors (Neuropeptide Y Receptor)IBA 12/2005
1	Neuropeptide YIBA 12/2005
1	Kainic Acid (Kainate)IBA 12/2005
1	Pro-Opiomelanocortin (Proopiomelanocortin)IBA 03/2004
1	neuropeptide Y2 receptorIBA 06/2002

Therapy/Procedure

3	Therapeutics 12/2018 - 02/2013
2	Analgesia 01/2021 - 01/2020
1	Hepatectomy 01/2020